These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 37545260)

  • 21. Disease modification in Parkinson's disease.
    Henchcliffe C; Severt WL
    Drugs Aging; 2011 Aug; 28(8):605-15. PubMed ID: 21812497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protocol for PD SENSORS: Parkinson's Disease Symptom Evaluation in a Naturalistic Setting producing Outcome measuRes using SPHERE technology. An observational feasibility study of multi-modal multi-sensor technology to measure symptoms and activities of daily living in Parkinson's disease.
    Morgan C; Craddock I; Tonkin EL; Kinnunen KM; McNaney R; Whitehouse S; Mirmehdi M; Heidarivincheh F; McConville R; Carey J; Horne A; Rolinski M; Rochester L; Maetzler W; Matthews H; Watson O; Eardley R; Whone AL
    BMJ Open; 2020 Nov; 10(11):e041303. PubMed ID: 33257491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antidepressants Trial in Parkinson's Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson's disease.
    Schrag A; Carroll C; Duncan G; Molloy S; Grover L; Hunter R; Brown R; Freemantle N; Whipps J; Serfaty MA; Lewis G
    BMC Neurol; 2022 Dec; 22(1):474. PubMed ID: 36510237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does the 5-2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries.
    Malaty IA; Martinez-Martin P; Chaudhuri KR; Odin P; Skorvanek M; Jimenez-Shahed J; Soileau MJ; Lindvall S; Domingos J; Jones S; Alobaidi A; Jalundhwala YJ; Kandukuri PL; Onuk K; Bergmann L; Femia S; Lee MY; Wright J; Antonini A
    BMC Neurol; 2022 Jan; 22(1):35. PubMed ID: 35073872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient Experience in Early-Stage Parkinson's Disease: Using a Mixed Methods Analysis to Identify Which Concepts Are Cardinal for Clinical Trial Outcome Assessment.
    Morel T; Cleanthous S; Andrejack J; Barker RA; Blavat G; Brooks W; Burns P; Cano S; Gallagher C; Gosden L; Siu C; Slagle AF; Trenam K; Boroojerdi B; Ratcliffe N; Schroeder K
    Neurol Ther; 2022 Sep; 11(3):1319-1340. PubMed ID: 35778541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
    Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS
    Lancet Neurol; 2017 Nov; 16(11):908-916. PubMed ID: 28958801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort.
    Regnault A; Boroojerdi B; Meunier J; Bani M; Morel T; Cano S
    J Neurol; 2019 Aug; 266(8):1927-1936. PubMed ID: 31073716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations.
    Webster L; Groskreutz D; Grinbergs-Saull A; Howard R; O'Brien JT; Mountain G; Banerjee S; Woods B; Perneczky R; Lafortune L; Roberts C; McCleery J; Pickett J; Bunn F; Challis D; Charlesworth G; Featherstone K; Fox C; Goodman C; Jones R; Lamb S; Moniz-Cook E; Schneider J; Shepperd S; Surr C; Thompson-Coon J; Ballard C; Brayne C; Burke O; Burns A; Clare L; Garrard P; Kehoe P; Passmore P; Holmes C; Maidment I; Murtagh F; Robinson L; Livingston G
    Health Technol Assess; 2017 May; 21(26):1-192. PubMed ID: 28625273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bromocriptine versus levodopa in early Parkinson's disease.
    Ramaker C; van Hilten JJ
    Cochrane Database Syst Rev; 2000; (3):CD002258. PubMed ID: 10908538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How should we be using biomarkers in trials of disease modification in Parkinson's disease?
    Vijiaratnam N; Foltynie T
    Brain; 2023 Dec; 146(12):4845-4869. PubMed ID: 37536279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parkinson's Disease Multimodal Complex Treatment improves motor symptoms, depression and quality of life.
    Scherbaum R; Hartelt E; Kinkel M; Gold R; Muhlack S; Tönges L
    J Neurol; 2020 Apr; 267(4):954-965. PubMed ID: 31797086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simvastatin as a neuroprotective treatment for Parkinson's disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study.
    Carroll CB; Webb D; Stevens KN; Vickery J; Eyre V; Ball S; Wyse R; Webber M; Foggo A; Zajicek J; Whone A; Creanor S
    BMJ Open; 2019 Oct; 9(10):e029740. PubMed ID: 31594876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
    Rolinski M; Fox C; Maidment I; McShane R
    Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD006504. PubMed ID: 22419314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-hypertensive drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies and clinical trials.
    Rees K; Stowe R; Patel S; Ives N; Breen K; Ben-Shlomo Y; Clarke CE
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008535. PubMed ID: 22071852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical progression of Parkinson's disease.
    Poewe W; Mahlknecht P
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S28-32. PubMed ID: 20123553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physical exercise for people with Parkinson's disease: a systematic review and network meta-analysis.
    Ernst M; Folkerts AK; Gollan R; Lieker E; Caro-Valenzuela J; Adams A; Cryns N; Monsef I; Dresen A; Roheger M; Eggers C; Skoetz N; Kalbe E
    Cochrane Database Syst Rev; 2023 Jan; 1(1):CD013856. PubMed ID: 36602886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigating trial design variability in trials of disease-modifying therapies in Parkinson's disease: a scoping review protocol.
    Zeissler ML; Boey T; Chapman D; Rafaloff G; Dominey T; Raphael KG; Buff S; Pai HV; King E; Sharpe P; O'Brien F; Carroll CB
    BMJ Open; 2023 Dec; 13(12):e071641. PubMed ID: 38070893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acceptability to patients, carers and clinicians of an mHealth platform for the management of Parkinson's disease (PD_Manager): study protocol for a pilot randomised controlled trial.
    Antonini A; Gentile G; Giglio M; Marcante A; Gage H; Touray MML; Fotiadis DI; Gatsios D; Konitsiotis S; Timotijevic L; Egan B; Hodgkins C; Biundo R; Pellicano C;
    Trials; 2018 Sep; 19(1):492. PubMed ID: 30217235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson's disease: the LEAP-study.
    Verschuur CV; Suwijn SR; Post B; Dijkgraaf M; Bloem BR; van Hilten JJ; van Laar T; Tissingh G; Deuschl G; Lang AE; de Haan RJ; de Bie RM
    BMC Neurol; 2015 Nov; 15():236. PubMed ID: 26584951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.